Introduction: Guidelines for distribution and use of blood products have been established for both blood transfusion institution and hospitals, in particular for the use of Rh (D)-incompatible platelet concentrates. The aim of this study was to evaluate: 1) the rate of attribution for the Rh (D)-incompatible platelets concentrates, 2) the immunisation prophylaxis practices, 3) the immunological consequences using short and medium term follow-up of transfused patients.
Methods: Patients with Rh (D)-incompatible platelets concentrate administered during the year 2003 at Rouen University Hospital were retrospectively selected. Patients on transfusion were described. The relationship of various factors with the injection as well as the appearance of allo-immunization was statistically tested.
Results: During a year, 280 Rh (D)-incompatible platelets concentrates were administered to 67 patients. Immunisation prophylaxis by injection of Ig anti-D was not systematically performed. Four immunizations in the Rhesus group system were identified: 2 against D antigen (Ag), 1 against E Ag and 1 against C Ag. Immunisations against D Ag occurred for two younger women considered as immunodeficient. Immunization prophylaxis was more frequent in poly-transfused patients. However no difference was observed for the other factors.
Conclusion: Compatibility concerning Rhesus (D) is not always possible. The immunization against red cells persists, in particular against the antigens of the Rhesus group system and moreover for the immunodeficient patients. Recommendations for immunization prophylaxis by injection of specific anti-D immune-globulin (Ig) could be reconsidered.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.tracli.2005.07.002 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Anti-D immunization after D positive platelet transfusions in D negative recipients: A systematic review and meta-analysis.
Transfusion
May 2024
Department of Experimental Immunohematology, Sanquin Research, Amsterdam, The Netherlands.
Article Synopsis
- Anti-D antibodies can develop in D- patients after they receive D+ platelet transfusions, which is a concern for women of childbearing age due to potential risks for their newborns.
- A systematic review of 22 studies found that 3.3% of D- patients formed anti-D antibodies after receiving D+ platelets, with women and those receiving whole blood-derived platelets having higher rates.
- The study suggests implementing anti-D prophylaxis for women who receive D+ platelets to minimize the risk of hemolytic disease in future pregnancies.
Predisposing factors for anti-D immune response in D patients with chronic liver disease transfused with D platelet concentrates.
Transfusion
April 2019
Etablissement Français du Sang Ile de France, Hôpital Henri Mondor, Créteil, France.
Background: Recent reports have indicated that the risk of anti-D alloimmunization following D-incompatible platelet (PLT) transfusion is low in hematology and oncology patients. We investigated the rate of anti-D alloimmunization in RhD-negative (D ) patients with chronic liver disease transfused with D platelet concentrates (PCs) and the factors involved, at a liver transplant (LT) center.
Study Design And Methods: We reviewed the blood bank database from January 2003 to October 2016.
Prospective surveillance of D- recipients of D+ apheresis platelets: alloimmunization against D is not detected.
Transfusion
June 2015
Transfusion Medicine Service, UMass Memorial Medical Center, Worcester, Massachusetts.
Background: Recent retrospective studies indicate that D- recipients of D+ apheresis platelets (PLTs) are not alloimmunized to D. Our hospital policy is to offer RhIG to D- women of childbearing age who received D+ apheresis PLTs but not to other D- recipients of D+ apheresis PLTs. We instituted prospective surveillance of the D- recipients who were not given RhIG.
View Article and Find Full Text PDFLow frequency of anti-D alloimmunization following D+ platelet transfusion: the Anti-D Alloimmunization after D-incompatible Platelet Transfusions (ADAPT) study.
Br J Haematol
February 2015
Department of Haemotherapy and Haemostasis, Hospital Clínic, IDIBAPS, UB, Barcelona, Spain; Clinical Center, Department of Transfusion Medicine, National Institutes of Health, Bethesda, MD, USA.
The reported frequency of D alloimmunization in D- recipients after transfusion of D+ platelets varies. This study was designed to determine the frequency of D alloimmunization, previously reported to be an average of 5 ± 2%. A primary anti-D immune response was defined as the detection of anti-D ≥ 28 d following the first D+ platelet transfusion.
View Article and Find Full Text PDFAnti-D alloimmunization after D-incompatible platelet transfusions: a 14-year single-institution retrospective review.
Transfusion
March 2014
Department of Pathology, Beth Israel Deaconess Medical Center, Boston, Massachusetts.
Background: A small, but immunogenic dose of red blood cells (RBCs) may be contained in apheresis platelets (PLTs). Attempts are made to provide D- recipients with D- PLTs to prevent anti-D alloimmunization and the potential for hemolytic disease of the fetus and newborn. Beth Israel Deaconess Medical Center has a policy that when necessary to transfuse D+ PLTs to D- patients, we recommend that RhIG be given when the patient is a woman of child-bearing age or a potential liver transplant patient.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!